Top News

Ascenion Mediates Licence Agreement between HZI and U.S. Biopharmaceutical Company on Novel Anti-Infective Compounds

SBA News Network, 06.03.2015

Ascenion, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has negotiated a licence agreement providing US-based Spero Therapeutics with exclusive rights to develop and commercialize a series of novel anti-infective compounds discovered at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a HZI branch.


Diapharm verstärkt Laborteam

transkript, 05.03.2015

Next Event


Community Login

Bachem Holding AG

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery